Syngene International Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Syngene International Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 17% in 3 years, but profit fell: ₹28 less profit per ₹100 of extra sales. Lower than 96% of Healthcare companies in India.
- Debt Due Cover Ratio: Debt due within a year is covered 97.4 times by its yearly operating cash. Higher than 96% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹236 of operating cash. Higher than 90% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹236Over the last 3 years, every ₹100 of reported profit came with ₹236 of operating cash.
Higher than 90% of Healthcare companies in India.
Self-Funding Ratio
1.9×Over the last 3 years its own operating cash covered its investment spending (capex) 1.9 times.
Higher than 66% of Healthcare companies in India.
Cash Locked Ratio
₹3For every ₹100 of sales, ₹3 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹16 tied up three years earlier.
Less money tied up than 83% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
−₹28Sales grew 17% in 3 years, but profit fell: ₹28 less profit per ₹100 of extra sales.
Lower than 96% of Healthcare companies in India.
Asset Productivity Ratio
+17% / +21%In 3 years sales changed by +17% while total assets changed by +21%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
97.4×Debt due within a year is covered 97.4 times by its yearly operating cash.
Higher than 96% of Healthcare companies in India.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Higher than 82% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 66% of Healthcare companies in India.
Tangible Net Worth Ratio
99%Of every ₹100 of net worth, ₹99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 67% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Syngene International Limited owes ₹0.31 for every ₹1 it owns. Net profit fell 36% in the year to Mar 2026, and shrank 12% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
66.8Investors pay ₹66.8 for every ₹1 of Syngene International Limited's yearly profit, higher than 81% of Healthcare companies in India.
P/B ratio
3.05The share price is 3.05 times Syngene International Limited's book value per share, lower than 71% of Healthcare companies in India.
Market cap
₹14,744 CrThe total market value of all of Syngene International Limited's shares at today's price (share price × number of shares), larger than 71% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹4,839 CrWhat Syngene International Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹120.40Net worth divided by the number of shares. The share price of ₹366.85 is 3.0 times this, which is the P/B above.
Return on equity (ROE)
4.6%Syngene International Limited earned 4.6% on its shareholders' money over the last year, lower than 84% of Healthcare companies in India.
Owes vs Owns
0.31×Syngene International Limited owes ₹0.31 for every ₹1 it owns (low), lower than 64% of Healthcare companies in India.
Dividend yield
0.36%Syngene International Limited pays 0.36% of its share price as dividends a year, lower than 52% of dividend-paying Healthcare companies in India.
Revenue growth
+3%Revenue rose 3% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Profit growth
-36%Net profit fell 36% in the year to Mar 2026, and shrank 12% a year on average over 3 years.
Profit margin
8.8%Syngene International Limited keeps ₹9 of every ₹100 of revenue as net profit.
Cash quality
2.9×Cash from Syngene International Limited's business was 2.9× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
12.4×Syngene International Limited's operating profit covered its interest costs 12.4 times in the year to Mar 2026.
Cash vs debt
Net cashSyngene International Limited held ₹831 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Syngene International Limited's P/E ratio?
Investors pay ₹66.8 for every ₹1 of Syngene International Limited's yearly profit, higher than 81% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Syngene International Limited: ₹14,744 Cr ÷ ₹4,839 Cr (31 Mar 2026) = 3.0.
What is Syngene International Limited's return on equity?
Syngene International Limited earned 4.6% on its shareholders' money over the last year, lower than 84% of Healthcare companies in India.
How much does Syngene International Limited owe compared with what it owns?
Syngene International Limited owes ₹0.31 for every ₹1 it owns (low), lower than 64% of Healthcare companies in India.
Does Syngene International Limited pay a dividend?
Yes. Syngene International Limited pays 0.36% of its share price as dividends a year, lower than 52% of dividend-paying Healthcare companies in India.
Is Syngene International Limited's revenue growing?
Revenue rose 3% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.